Cellectar Biosciences (CLRB) - Quarterly EPS earnings growth

Official company branding of Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences radiopharmaceutical development remains independent of macroeconomic trends, relying instead on its patent portfolio and clinical trial stages. The quarterly earnings per share trend demonstrates business resilience, with the parameter value standing at 68.10. High profit potential following drug registration ensures scalability, while the success of Iopofosine has solidified the brand's status as an authoritative player in hematology.

Cellectar Biosciences, Inc. (CLRB) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/12/2026

Analytical breakdowns for Cellectar Biosciences

- market value and analyst target forecast:
Price Chart Cellectar Biosciences, Inc.|CLRB - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Cellectar|CLRB - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Cellectar Biosciences|CLRB - Total Stockholders' Equity|Market Value to Book Value Ratio cellectar.com|CLRB - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Cellectar Biosciences|CLRB - Long-Term Liabilities to Capital|Short-Term Debt to Capital Cellectar Biosciences|CLRB - Company Total Indebtedness|Debt to Book Value Cellectar|CLRB - Long-Term Debt|Company Current Liabilities Cellectar Biosciences|Quick Liquidity Indicator cellectar.com
- earnings and market multiples details:
CLRB - Profit After Payment of Taxes|Projected Future Earnings Cellectar Biosciences|CLRB - Company Value to Net Income|Forward P/E Multiple Cellectar|CLRB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cellectar|CLRB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Cellectar Biosciences|CLRB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months cellectar.com|CLRB - Earnings per share trend in current year|Expected earnings per share growth for next year Cellectar Biosciences
Fundamental company analysis:Cellectar Biosciences, Inc., CLRB
Manufactured product of Cellectar Corp

For Cellectar Biosciences (CLRB), which is developing targeted radiopharmaceuticals in oncology, earnings per share dynamics serve as an indicator of the efficiency of innovation capitalization. By analyzing the history of quarterly EPS changes, an investor assesses the real growth of net income, stripped of accounting adjustments, which allows for the differentiation of fundamental business growth from short-term speculative price fluctuations.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring, Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla, Inc.)|LIXT (Lixte Biotechnology, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (biolinerx.com)|Can-Fite BioPharma Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (Aprea Therapeutics)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion Therapeutics (SLXN)|Year-over-year earnings per share growth for the last twelve months NuCana PLC|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com